

## Special Issue

# Advances in Pancreatic Cancer: Exploring Biomarkers and Prognostic Predictors

### Message from the Guest Editor

With our Special Issue, titled "Advances in Pancreatic Cancer: Exploring Biomarkers and Prognostic Predictors", we hope to shape the future of pancreatic cancer care and strive towards improved patient outcomes. For this Special Issue, we invite submissions on cutting-edge research in the field of pancreatic cancer diagnosis and prognosis, thereby contributing to advancements that will ultimately enhance patient prognosis. Topics of interest include the following: novel biomarkers (liquid biopsy, proteomics, metabolomics, etc.); established and emerging prognostic factors (tumor microenvironment, genetic alterations, and inflammatory markers); and their clinical implications for early detection, risk stratification, and personalized management. Submissions in forms of original research articles, reviews, and perspectives are welcome. Please submit your manuscripts by June 2026, so we collectively work toward a brighter future for pancreatic cancer patients.

### Guest Editor

Dr. Makoto Abue

Departments of Gastroenterology, Miyagi Cancer Center, Nodayama 47-1, Medeshima-Shiote, Natori, Miyagi, Japan

### Deadline for manuscript submissions

30 June 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/243748](https://mdpi.com/si/243748)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)